# HER2 Expression of CTC to Predict Response in HER2-positive Advanced Breast Cancer Patients Treated With ADC

> **NCT05834686** · — · UNKNOWN · sponsor: **Beijing 302 Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** HER2 expression of circulating tumor cells

## Key facts

- **NCT ID:** NCT05834686
- **Lead sponsor:** Beijing 302 Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-01
- **Primary completion:** 2024-12
- **Final completion:** 2025-04
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05834686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05834686, "HER2 Expression of CTC to Predict Response in HER2-positive Advanced Breast Cancer Patients Treated With ADC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05834686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*